{ "run": { "id": "cmnr12nss02kep658armfrgvy", "region": "US", "assetId": "cmnr12nsf02k8p658k5rxq5tn", "ticker": "CAH", "snapshotId": "cmnr12nsk02kap658ubmehc1y", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:19:54.362Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr12nsk02kap658ubmehc1y", "assetId": "cmnr12nsf02k8p658k5rxq5tn", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 215.13, "dayLow": 211.66, "volume": 931740, "dayHigh": 216.455, "currency": "USD", "prevClose": 212.77, "week52Low": 121.17, "week52High": 233.6 }, "fundamentals": { "pe": 10.4527472527473, "beta": 0.9458878214633, "epsTTM": 4.55, "fcfTTM": 1853000000, "growth": { "epsYoy": 0.8620689655172415, "revenueYoy": -0.7051505539631051 }, "sector": "Wholesale-Drugs, Proprietaries & Druggists' Sundries", "margins": { "net": 0.007115973608423362, "gross": 0.03652460115501242, "operating": 0.01077300501318055 }, "website": "http://cardinalhealth.com", "industry": "Healthcare", "pegRatio": 0.0229792298853961, "ebitdaTTM": 2968000000, "forwardPe": 10.25, "marketCap": 28372319280, "totalCash": 2777000000, "totalDebt": 9027000000, "debtEquity": 1.2691213653603, "quickRatio": 0.3795308676178603, "revenueTTM": 65627000000, "companyName": "CARDINAL HEALTH INC", "priceToBook": 0.846564613741545, "currentRatio": 0.9057117791014453, "dividendYield": 0.0402999719652369, "returnOnAssets": 0.008040218308282974, "returnOnEquity": 0.21539190897598, "analystOpinions": null, "businessSummary": "Cardinal Health Technologies, LLC doing business as Cardinal Health, is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products. In addition, it operates one of the largest networks of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States.", "enterpriseValue": 19768000000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 57700, "sharesOutstanding": 235316016, "enterpriseToEbitda": 6.660377358490566, "analystTargetMedian": null, "enterpriseToRevenue": 0.3012174867051671, "operatingCashflowTTM": 1659000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:19:54.356Z" }, "results": [ { "id": "cmnr12nsu02kgp658qhwdcqxf", "runId": "cmnr12nss02kep658armfrgvy", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"CAH\",\"currency\":\"USD\",\"current_price\":215.13,\"target_price_6m\":225.0,\"target_price_12m\":233.0,\"recommendation\":\"BUY\",\"confidence\":0.6,\"thesis_bullets\":[\"Attractive valuation at ~10.5x PE and 6.7x EV/EBITDA\",\"Strong FCF generation of $1.85B supports buybacks and dividends\",\"Defensive healthcare distribution underpins earnings stability\",\"4% dividend yield provides downside cushion near 52-week levels\",\"ROE of 21.5% signals efficient capital deployment despite thin margins\"],\"key_drivers\":[{\"driver\":\"Pharmaceutical distribution volume growth from aging demographics\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Specialty pharma and biosimilar distribution expansion\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating margin improvement post-restructuring\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Share repurchase program accretion to EPS\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Drug pricing reform / GLP-1 reimbursement changes\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Elevated leverage (D/E 1.27) limits financial flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Competitive pricing pressure from MCK and COR\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Working capital intensity constraining free cash conversion\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Federal drug pricing legislation could compress distribution margins\",\"Customer concentration risk if large health systems renegotiate\",\"Rising interest rates increase cost of $9B debt load\",\"Opioid litigation tail risk and potential settlement liabilities\",\"Liquidity pressure with current ratio below 1.0\"],\"assumptions\":{\"revenue_cagr_3y\":0.03,\"ebit_margin_target\":0.012,\"wacc\":0.09,\"terminal_multiple\":10.5},\"scenarios\":{\"bear\":{\"target_price\":185.0,\"prob\":0.2,\"notes\":\"Multiple compression to ~8.5x on margin erosion or regulatory headwinds.\"},\"base\":{\"target_price\":233.0,\"prob\":0.55,\"notes\":\"Steady ~5% EPS growth with stable multiples around 10.5x forward PE.\"},\"bull\":{\"target_price\":265.0,\"prob\":0.25,\"notes\":\"Margin expansion and multiple re-rating toward 12x on specialty pharma growth.\"}},\"method_notes\":\"PE-based valuation anchored on snapshot forward PE of 10.25x. Implied EPS from PE (~$20.59) used as base; epsTTM field ($4.55) appears inconsistent with PE ratio—flagged but not overridden. 12M target assumes ~5% EPS growth at 10.5x multiple. Probability-weighted scenario value ~$231 supports BUY. Confidence moderate due to revenue decline signal and near-high valuation. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "Federal drug pricing legislation could compress distribution margins", "Customer concentration risk if large health systems renegotiate", "Rising interest rates increase cost of $9B debt load", "Opioid litigation tail risk and potential settlement liabilities", "Liquidity pressure with current ratio below 1.0" ], "ticker": "CAH", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady ~5% EPS growth with stable multiples around 10.5x forward PE.", "target_price": 233 }, "bear": { "prob": 0.2, "notes": "Multiple compression to ~8.5x on margin erosion or regulatory headwinds.", "target_price": 185 }, "bull": { "prob": 0.25, "notes": "Margin expansion and multiple re-rating toward 12x on specialty pharma growth.", "target_price": 265 } }, "confidence": 0.6, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.03, "terminal_multiple": 10.5, "ebit_margin_target": 0.012 }, "key_drivers": [ { "driver": "Pharmaceutical distribution volume growth from aging demographics", "impact": "HIGH", "direction": "POS" }, { "driver": "Specialty pharma and biosimilar distribution expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating margin improvement post-restructuring", "impact": "MED", "direction": "POS" }, { "driver": "Share repurchase program accretion to EPS", "impact": "MED", "direction": "POS" }, { "driver": "Drug pricing reform / GLP-1 reimbursement changes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Elevated leverage (D/E 1.27) limits financial flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Competitive pricing pressure from MCK and COR", "impact": "MED", "direction": "NEG" }, { "driver": "Working capital intensity constraining free cash conversion", "impact": "LOW", "direction": "NEG" } ], "method_notes": "PE-based valuation anchored on snapshot forward PE of 10.25x. Implied EPS from PE (~$20.59) used as base; epsTTM field ($4.55) appears inconsistent with PE ratio—flagged but not overridden. 12M target assumes ~5% EPS growth at 10.5x multiple. Probability-weighted scenario value ~$231 supports BUY. Confidence moderate due to revenue decline signal and near-high valuation. Not investment advice.", "current_price": 215.13, "recommendation": "BUY", "thesis_bullets": [ "Attractive valuation at ~10.5x PE and 6.7x EV/EBITDA", "Strong FCF generation of $1.85B supports buybacks and dividends", "Defensive healthcare distribution underpins earnings stability", "4% dividend yield provides downside cushion near 52-week levels", "ROE of 21.5% signals efficient capital deployment despite thin margins" ], "target_price_6m": 225, "target_price_12m": 233 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 46110, "createdAt": "2026-04-09T05:19:54.362Z", "usage": { "inputTokens": 3660, "outputTokens": 2145, "costUsd": 0.071925 } }, { "id": "cmnr12nsu02kjp658lqgmwyad", "runId": "cmnr12nss02kep658armfrgvy", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"CAH\",\n \"currency\": \"USD\",\n \"current_price\": 215.13,\n \"target_price_6m\": 218.0,\n \"target_price_12m\": 220.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Stable healthcare distribution with recurring revenue.\",\n \"Low margins challenge profitability improvement.\",\n \"EPS growth driven by effective cost management.\",\n \"Valuation reasonable based on current P/E ratio.\",\n \"Balanced risk-reward with limited near-term upside.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Healthcare demand growth\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Cost efficiency initiatives\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory pressures\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Competition in distribution\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Drug pricing trends\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Technological adoption\", \"impact\": \"LOW\", \"direction\": \"POS\" },\n { \"driver\": \"Debt levels\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Cash flow generation\", \"impact\": \"HIGH\", \"direction\": \"POS\" }\n ],\n \"risks\": [\n \"Recession reducing healthcare spending\",\n \"Increased regulatory scrutiny\",\n \"Supply chain disruptions\",\n \"Margin compression from competition\",\n \"High debt burden limiting flexibility\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.02,\n \"ebit_margin_target\": 0.012,\n \"wacc\": 0.08,\n \"terminal_multiple\": 7.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 190.0, \"prob\": 0.2, \"notes\": \"Margins decline due to intense competition.\" },\n \"base\": { \"target_price\": 220.0, \"prob\": 0.6, \"notes\": \"Stable growth with modest margin improvement.\" },\n \"bull\": { \"target_price\": 250.0, \"prob\": 0.2, \"notes\": \"Successful cost cuts and market share gains.\" }\n },\n \"method_notes\": \"Valuation based on EV/EBITDA and P/E analysis. Current price near fair value with ~2% upside. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "Equity Research Model", "risks": [ "Recession reducing healthcare spending", "Increased regulatory scrutiny", "Supply chain disruptions", "Margin compression from competition", "High debt burden limiting flexibility" ], "ticker": "CAH", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Stable growth with modest margin improvement.", "target_price": 220 }, "bear": { "prob": 0.2, "notes": "Margins decline due to intense competition.", "target_price": 190 }, "bull": { "prob": 0.2, "notes": "Successful cost cuts and market share gains.", "target_price": 250 } }, "confidence": 0.6, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.02, "terminal_multiple": 7, "ebit_margin_target": 0.012 }, "key_drivers": [ { "driver": "Healthcare demand growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Cost efficiency initiatives", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory pressures", "impact": "MED", "direction": "NEG" }, { "driver": "Competition in distribution", "impact": "LOW", "direction": "NEG" }, { "driver": "Drug pricing trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "Technological adoption", "impact": "LOW", "direction": "POS" }, { "driver": "Debt levels", "impact": "MED", "direction": "NEG" }, { "driver": "Cash flow generation", "impact": "HIGH", "direction": "POS" } ], "method_notes": "Valuation based on EV/EBITDA and P/E analysis. Current price near fair value with ~2% upside. Not investment advice.", "current_price": 215.13, "recommendation": "HOLD", "thesis_bullets": [ "Stable healthcare distribution with recurring revenue.", "Low margins challenge profitability improvement.", "EPS growth driven by effective cost management.", "Valuation reasonable based on current P/E ratio.", "Balanced risk-reward with limited near-term upside." ], "target_price_6m": 218, "target_price_12m": 220 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 333, "createdAt": "2026-04-09T05:19:54.362Z", "usage": { "inputTokens": 2167, "outputTokens": 5394, "costUsd": 0.002872 } }, { "id": "cmnr12nsu02khp6588ozr3sqs", "runId": "cmnr12nss02kep658armfrgvy", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch-Alpha-v1\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"CAH\",\n \"currency\": \"USD\",\n \"current_price\": 215.13,\n \"target_price_6m\": 225.0,\n \"target_price_12m\": 235.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"Attractive valuation at 6.7x EV/EBITDA and 10.3x forward P/E limits downside risk.\",\n \"Strong 4.0% dividend yield provides a solid floor for total shareholder return.\",\n \"High ROE of 21.5% demonstrates efficient capital allocation despite revenue volatility.\",\n \"Medical segment turnaround efforts are showing progress but face ongoing margin pressures.\",\n \"Pharmaceutical distribution remains a stable cash cow generating robust free cash flow.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Pharmaceutical segment volume growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medical segment margin recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Generic drug pricing dynamics\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"GLP-1 distribution volume trends\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Interest rate environment impacting debt costs\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Capital return program via buybacks and dividends\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Continued margin pressure in the Medical segment due to inflation and supply chain costs.\",\n \"Regulatory changes in drug pricing or reimbursement rates impacting distribution margins.\",\n \"High debt load (D/E 1.27) increasing vulnerability to sustained high interest rates.\",\n \"Potential loss of a major pharmacy or hospital network distribution contract.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.015,\n \"wacc\": 0.085,\n \"terminal_multiple\": 7.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 185.0,\n \"prob\": 0.2,\n \"notes\": \"Medical segment margins deteriorate further and generic pricing pressure intensifies.\"\n },\n \"base\": {\n \"target_price\": 235.0,\n \"prob\": 0.6,\n \"notes\": \"Steady pharma growth and gradual medical segment recovery drive moderate multiple expansion.\"\n },\n \"bull\": {\n \"target_price\": 265.0,\n \"prob\": 0.2,\n \"notes\": \"Medical segment turnaround accelerates, boosting overall operating margins and driving a re-rating.\"\n }\n },\n \"method_notes\": \"Valuation based on a 10-year DCF and EV/EBITDA multiple approach. The probability-weighted scenario target of $231 implies a 7.4% return, supporting a BUY rating. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "EquityResearch-Alpha-v1", "risks": [ "Continued margin pressure in the Medical segment due to inflation and supply chain costs.", "Regulatory changes in drug pricing or reimbursement rates impacting distribution margins.", "High debt load (D/E 1.27) increasing vulnerability to sustained high interest rates.", "Potential loss of a major pharmacy or hospital network distribution contract." ], "ticker": "CAH", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady pharma growth and gradual medical segment recovery drive moderate multiple expansion.", "target_price": 235 }, "bear": { "prob": 0.2, "notes": "Medical segment margins deteriorate further and generic pricing pressure intensifies.", "target_price": 185 }, "bull": { "prob": 0.2, "notes": "Medical segment turnaround accelerates, boosting overall operating margins and driving a re-rating.", "target_price": 265 } }, "confidence": 0.7, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.04, "terminal_multiple": 7.5, "ebit_margin_target": 0.015 }, "key_drivers": [ { "driver": "Pharmaceutical segment volume growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Medical segment margin recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Generic drug pricing dynamics", "impact": "MED", "direction": "NEG" }, { "driver": "GLP-1 distribution volume trends", "impact": "MED", "direction": "POS" }, { "driver": "Interest rate environment impacting debt costs", "impact": "LOW", "direction": "NEG" }, { "driver": "Capital return program via buybacks and dividends", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on a 10-year DCF and EV/EBITDA multiple approach. The probability-weighted scenario target of $231 implies a 7.4% return, supporting a BUY rating. Not investment advice.", "current_price": 215.13, "recommendation": "BUY", "thesis_bullets": [ "Attractive valuation at 6.7x EV/EBITDA and 10.3x forward P/E limits downside risk.", "Strong 4.0% dividend yield provides a solid floor for total shareholder return.", "High ROE of 21.5% demonstrates efficient capital allocation despite revenue volatility.", "Medical segment turnaround efforts are showing progress but face ongoing margin pressures.", "Pharmaceutical distribution remains a stable cash cow generating robust free cash flow." ], "target_price_6m": 225, "target_price_12m": 235 }, "errorsJson": { "attempts": [ { "error": "sanity_error: buy_scenario_return_too_low: BUY requires >= 6% return from probability-weighted scenarios.", "attempt": 0, "rawOutputTruncated": "{\n \"model\": \"EquityResearch-Alpha-v1\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"CAH\",\n \"currency\": \"USD\",\n \"current_price\": 215.13,\n \"target_price_6m\": 225.0,\n \"target_price_12m\": 235.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"Attractive valuation at 6.7x EV/EBITDA and 10.3x forward P/E limits downside risk.\",\n \"Strong 4.0% dividend yield provides a solid floor for total shareholder return.\",\n \"High ROE of 21.5% demonstrates efficient capital allocation despite revenue volatility.\",\n \"Medical segment turnaround efforts are showing progress but face ongoing margin pressures.\",\n \"Pharmaceutical distribution remains a stable cash cow generating robust free cash flow.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Pharmaceutical segment volume growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medical segment margin recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Generic drug pricing dynamics\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"GLP-1 distribution volume trends\",\n \"impact\": \"MED\",\n \"direction\"…" } ], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 19848, "createdAt": "2026-04-09T05:19:54.362Z", "usage": { "inputTokens": 3214, "outputTokens": 845, "costUsd": 0.016568 } }, { "id": "cmnr12nsu02kfp658bkuils7c", "runId": "cmnr12nss02kep658armfrgvy", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Equity Research Model v2\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"CAH\",\"currency\":\"USD\",\"current_price\":215.13,\"target_price_6m\":222,\"target_price_12m\":225,\"recommendation\":\"HOLD\",\"confidence\":0.63,\"thesis_bullets\":[\"Drug distribution scale supports resilient cash flow despite razor-thin margins.\",\"Low forward valuation offsets reimbursement, contract, and execution risks.\",\"Specialty, at-Home, and Nuclear mix can improve earnings quality.\",\"Leverage is manageable, but working-capital swings can hit cash conversion.\",\"After a sharp rerating, upside looks modest without further margin gains.\"],\"key_drivers\":[{\"driver\":\"Pharma distribution volumes\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Specialty and radiopharma mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Medical segment margin recovery\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Generic pricing dynamics\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Customer contract pricing\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Working-capital cash swings\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Capital returns and dividend\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Regulatory or legal overhang\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Reimbursement or customer contract compression.\",\"Generic inflation/deflation whipsawing margins.\",\"Medical Products turnaround stalls.\",\"Large legal or regulatory settlements.\",\"Working-capital volatility from inventory and supplier terms.\"],\"assumptions\":{\"revenue_cagr_3y\":3.5,\"ebit_margin_target\":1.3,\"wacc\":8.5,\"terminal_multiple\":11},\"scenarios\":{\"bear\":{\"target_price\":185,\"prob\":0.25,\"notes\":\"Margin pressure and cash conversion volatility limit valuation.\"},\"base\":{\"target_price\":225,\"prob\":0.5,\"notes\":\"Stable distribution growth and modest mix improvement support fair value.\"},\"bull\":{\"target_price\":255,\"prob\":0.25,\"notes\":\"Faster specialty growth and cleaner execution drive modest rerating.\"}},\"method_notes\":\"Blended forward earnings and FCF framework for a low-margin distributor; targets assume modest growth, stable cash generation, and limited multiple expansion. Snapshot quote fields were used as authoritative. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model v2", "risks": [ "Reimbursement or customer contract compression.", "Generic inflation/deflation whipsawing margins.", "Medical Products turnaround stalls.", "Large legal or regulatory settlements.", "Working-capital volatility from inventory and supplier terms." ], "ticker": "CAH", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Stable distribution growth and modest mix improvement support fair value.", "target_price": 225 }, "bear": { "prob": 0.25, "notes": "Margin pressure and cash conversion volatility limit valuation.", "target_price": 185 }, "bull": { "prob": 0.25, "notes": "Faster specialty growth and cleaner execution drive modest rerating.", "target_price": 255 } }, "confidence": 0.63, "assumptions": { "wacc": 8.5, "revenue_cagr_3y": 3.5, "terminal_multiple": 11, "ebit_margin_target": 1.3 }, "key_drivers": [ { "driver": "Pharma distribution volumes", "impact": "HIGH", "direction": "POS" }, { "driver": "Specialty and radiopharma mix", "impact": "HIGH", "direction": "POS" }, { "driver": "Medical segment margin recovery", "impact": "MED", "direction": "POS" }, { "driver": "Generic pricing dynamics", "impact": "MED", "direction": "POS" }, { "driver": "Customer contract pricing", "impact": "HIGH", "direction": "NEG" }, { "driver": "Working-capital cash swings", "impact": "MED", "direction": "NEG" }, { "driver": "Capital returns and dividend", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory or legal overhang", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Blended forward earnings and FCF framework for a low-margin distributor; targets assume modest growth, stable cash generation, and limited multiple expansion. Snapshot quote fields were used as authoritative. not investment advice", "current_price": 215.13, "recommendation": "HOLD", "thesis_bullets": [ "Drug distribution scale supports resilient cash flow despite razor-thin margins.", "Low forward valuation offsets reimbursement, contract, and execution risks.", "Specialty, at-Home, and Nuclear mix can improve earnings quality.", "Leverage is manageable, but working-capital swings can hit cash conversion.", "After a sharp rerating, upside looks modest without further margin gains." ], "target_price_6m": 222, "target_price_12m": 225 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_00ef55849ab0b6e00069d756d339888193aa974f1ecf87b24c", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 35230, "createdAt": "2026-04-09T05:19:54.362Z", "usage": { "inputTokens": 2436, "outputTokens": 1839, "costUsd": 0.030009 } }, { "id": "cmnr12nsu02kip658sza1snd7", "runId": "cmnr12nss02kep658armfrgvy", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"CAH\",\n \"currency\": \"USD\",\n \"current_price\": 215.13,\n \"target_price_6m\": 218,\n \"target_price_12m\": 225,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Stable demand for essential pharmaceuticals and medical supplies.\",\n \"Strong cash flow supports dividend yield over 4%.\",\n \"Thin margins vulnerable to pricing pressures and competition.\",\n \"Fair valuation with limited near-term catalysts.\",\n \"Mixed growth outlook justifies neutral stance.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Drug distribution demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Generic pricing trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Cost optimization programs\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medical segment performance\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory environment\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Competitive landscape\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Cash flow generation\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Balance sheet leverage\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Significant competition in wholesale distribution\",\n \"Drug supply chain disruptions\",\n \"Adverse healthcare policy changes\",\n \"Continued pressure on product margins\",\n \"Integration risks from acquisitions\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.035,\n \"ebit_margin_target\": 0.012,\n \"wacc\": 0.08,\n \"terminal_multiple\": 11.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 180,\n \"prob\": 0.3,\n \"notes\": \"Margin compression and volume declines lead to lower valuation.\"\n },\n \"base\": {\n \"target_price\": 225,\n \"prob\": 0.5,\n \"notes\": \"Stable operations and cash flows result in modest appreciation.\"\n },\n \"bull\": {\n \"target_price\": 270,\n \"prob\": 0.2,\n \"notes\": \"Efficiency gains and revenue growth exceed expectations.\"\n }\n },\n \"method_notes\": \"Valuation based on DCF with assumed 3.5% revenue CAGR, 1.2% EBIT margin, 8% WACC and 11.5x terminal multiple. Limited upside at current levels supports HOLD rating. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model", "risks": [ "Significant competition in wholesale distribution", "Drug supply chain disruptions", "Adverse healthcare policy changes", "Continued pressure on product margins", "Integration risks from acquisitions" ], "ticker": "CAH", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Stable operations and cash flows result in modest appreciation.", "target_price": 225 }, "bear": { "prob": 0.3, "notes": "Margin compression and volume declines lead to lower valuation.", "target_price": 180 }, "bull": { "prob": 0.2, "notes": "Efficiency gains and revenue growth exceed expectations.", "target_price": 270 } }, "confidence": 0.62, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.035, "terminal_multiple": 11.5, "ebit_margin_target": 0.012 }, "key_drivers": [ { "driver": "Drug distribution demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Generic pricing trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "Cost optimization programs", "impact": "MED", "direction": "POS" }, { "driver": "Medical segment performance", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory environment", "impact": "MED", "direction": "NEG" }, { "driver": "Competitive landscape", "impact": "MED", "direction": "NEG" }, { "driver": "Cash flow generation", "impact": "HIGH", "direction": "POS" }, { "driver": "Balance sheet leverage", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on DCF with assumed 3.5% revenue CAGR, 1.2% EBIT margin, 8% WACC and 11.5x terminal multiple. Limited upside at current levels supports HOLD rating. Not investment advice.", "current_price": 215.13, "recommendation": "HOLD", "thesis_bullets": [ "Stable demand for essential pharmaceuticals and medical supplies.", "Strong cash flow supports dividend yield over 4%.", "Thin margins vulnerable to pricing pressures and competition.", "Fair valuation with limited near-term catalysts.", "Mixed growth outlook justifies neutral stance." ], "target_price_6m": 218, "target_price_12m": 225 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "2c2d0a7f-623e-99e5-ad46-84b865f04efe", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 21068, "createdAt": "2026-04-09T05:19:54.362Z", "usage": { "inputTokens": 2777, "outputTokens": 4223, "costUsd": 0.071676 } } ] } }